Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NMT Pharma of Singapore In-licenses Cancer Drug from US's CAO Pharma

publication date: Apr 11, 2016
Singapore's NMT Pharma in-licensed worldwide rights to a cancer drug co-developed by CAO Pharma of Houston, Texas and NMT. CAO developed CZ-48, an analogue of camptothecin, to become active only within tumors. A well-known cytotoxic agent, camptothecin is used in traditional Chinese medicine and is derived from the bark of the camptotheca tree. Other variants of the drug are the approved drugs topotecan and irinotecan. NMT is a CRO with technology that improves the bioavailability of drug candidates. Financial details were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital